Shukra Pharmaceuticals Limited (BOM:524632)
India · Delayed Price · Currency is INR | Market Cap | 18.50B +88.1% |
| Revenue (ttm) | 645.69M +93.3% |
| Net Income | 291.61M +256.7% |
| EPS | 0.40 +111.8% |
| Shares Out | 437.88M |
| PE Ratio | 106.52 |
| Forward PE | n/a |
| Dividend | 0.01 (0.02%) |
| Ex-Dividend Date | Sep 18, 2025 |
| Volume | 108,412 |
| Average Volume | 241,886 |
| Open | 40.13 |
| Previous Close | 42.24 |
| Day's Range | 40.13 - 40.13 |
| 52-Week Range | 11.74 - 65.26 |
| Beta | 0.72 |
| RSI | 45.11 |
| Earnings Date | Feb 4, 2026 |
About Shukra Pharmaceuticals
Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin ... [Read more]
Financial Performance
In fiscal year 2025, Shukra Pharmaceuticals's revenue was 325.87 million, a decrease of -56.30% compared to the previous year's 745.73 million. Earnings were 95.75 million, a decrease of -48.35%.
Financial StatementsNews
Pharma firm set to invest Rs 587cr in Medical Device Park
Noida: Yamuna Expressway Industrial Development Authority (YEIDA) has issued a letter of intent (LoI) to Shukra Pharmaceuticals for setting up an adva.
Shukra Pharmaceuticals enters MoU with Borns Medical Robotics to bring AI-powered surgical robots to India and South Asia
Shukra Pharmaceuticals Limited has announced a strategic move into advanced medical technology after entering into a Memorandum of Understanding (MoU)...
Shukra Pharma shares jump over 2% after securing authorization to act as DGAFMS distributor across india
Shukra Pharmaceuticals saw its shares climb more than 2% after the company confirmed that it has received an official Authorization...
Shukra Pharmaceuticals receives authorization to act as DGAFMS distributor across india
Shukra Pharmaceuticals Limited has announced that it received an official Authorization Letter on December 3, 2025, from Integra Medical Devices...
Shukra Pharmaceuticals enters Robotic Surgery segment with Meril Healthcare authorization
Shukra Pharmaceuticals Limited has announced a major milestone in its business expansion. The company has received authorization from Meril Healthcare...
Shukra Pharmaceuticals secures Pan-India distribution rights from Wockhardt
Shukra Pharmaceuticals Limited has been granted non-exclusive rights by Wockhardt Limited for distributing products across all ESIC/ESIS and Defence hospitals in India. The agreement, valid till March...
Shukra Pharmaceuticals rises nearly 2% as company opens four new branch offices
Shares of Shukra Pharmaceuticals Limited rose nearly 2% to ₹19.57 today after the company announced the opening of four new branch offices in major Indian cities — Mumbai, Gurgaon (NCR), Bangalore, an...
Shukra Pharmaceuticals opens new branch offices in Mumbai, Gurgaon, Bangalore, and Kolkata to boost market reach
Shukra Pharmaceuticals Limited announced the opening of four new branch offices in key Indian cities — Mumbai, Gurgaon (NCR), Bangalore, and Kolkata — as part of its strategic growth initiative aimed ...
Shukra Pharmaceuticals shares surge 90% in past one month; Check details
Shukra Pharmaceuticals has witnessed a dramatic surge in its stock price, rising by an impressive 90% in the past month. As of January 24, 2025, the stock closed at 224.60. Performance Breakdown: Shuk...
Shukra Pharmaceuticals shares surge 166% in past one month; Check details
Shukra Pharmaceuticals has witnessed a remarkable surge in its stock price, with shares rising by an astounding 166% over the past month. As of January 10, 2025, the stock closed at ₹184.45, marking a...